UK-based medical endowment Wellcome Trust is creating a £200m ($300m) investment company to invest in start-up biotechnology companies. The company, temporarily called Sigma, will focus on UK and European transformational technologies with potential for high returns over at least a decade. Nigel Keen, chairman of public technology companies in the healthcare and electronics industries, including…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
